Phase 2 Data from "ASTRAEUS" Trial Of Mereo BioPharma's Alvelestat In Alpha-1 Antitrypsin Deficiency-Associated Lung Disease Presented At The 2023 American Thoracic Society International Conference
Portfolio Pulse from Benzinga Newsdesk
Mereo BioPharma presented Phase 2 data from the ASTRAEUS trial of alvelestat for Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) at the 2023 American Thoracic Society International Conference. The data showed significant biomarker reductions and Mereo is preparing for a pivotal Phase 3 study.
May 23, 2023 | 5:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mereo BioPharma's alvelestat demonstrated significant biomarker reductions in Phase 2 ASTRAEUS trial for AATD-LD treatment, leading to preparations for a pivotal Phase 3 study.
The positive Phase 2 data presented at the 2023 American Thoracic Society International Conference indicates that alvelestat has potential as a treatment for AATD-LD. This will likely have a positive impact on MREO's stock price in the short term as the company moves forward with preparations for a pivotal Phase 3 study, which could lead to regulatory approvals in the US and EU if successful.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100